Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
December 21 2023 - 5:45PM
Dow Jones News
By Ben Glickman
Ultragenyx Pharmaceutical agreed to pay $6 million to resolve
allegations by the Justice Department related to false Medicare and
Medicaid claims.
The DOJ said Thursday the allegations related to Ultragenyx
paying for free genetic tests for patients, as well as buying test
results to induce prescriptions of its drug Crysvita, a treatment
for X-linked hypophosphatemia, or XLH.
Insurers may require a genetic test indicating XLH before
prescribing Crysvita, and the DOJ said Ultragenyx paid a genetic
testing laboratory to conduct testing on patients for free and
provide results to health-care providers.
DOJ argued Ultragenyx caused the submission of false claims to
Medicare and Medicaid by paying for these tests as a form of
kickback.
DOJ alleged Ultragenyx also paid the laboratory to provide test
results to the company, which were then used for marketing
Crysvita.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 17:30 ET (22:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024
